Scientific publications

Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson’s disease psychosis 

Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, Pär Halje, Luciano Censoni, Emilio Garro-Martínez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson. 

The paper was published on 19 Februariy, 2024. DOI: https://doi.org/10.1016/j.neurot.2024.e00334

RESULTS FROM IRL790C005 – A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY EVALUATING THE EFFICACY OF MESDOPETAM ON DAILY ON-TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON’S DISEASE 

A. ANTONINI, S. WATERS, C. SONESSON, J. LANDSTRÖM, N. WATERS, J. TEDROFF.  Poster presented at the the MDS Congress 2023 on August 28, 2023.

Behavioral and electrophysiological characterization of antipsychotic treatments in a rodent model of Parkinson’s disease psychosis’

T. Loredan Stan, A. Ronaghi, S. Barrientos, P. Halje, L. Censoni, E. Garro Martínez, E. Malinina, K. Sahlholm, P. Petersson. Poster presented at the Neuroscience 2022 by Society for Neuroscience on November 15, 2022.

Behavioral and electrophysiological characterization of the antidyskinetic treatments in a rodent model of PD-LID

A. Ronaghi, T. Loredan Stan, S. Barrientos Baeza, S. Sulis Sato, E. Malinina, L. Censoni, P. Halje, P. Petersson. Poster presented at the Neuroscience 2022 by Society for Neuroscience on November 15, 2022.

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

Sjöberg F, Waters S, Löfberg B, Sonesson C, Waters N, Tedroff J. Pharmacol Res Perspect. 2021;9:e00792. https://doi.org/10.1002/prp2.792.

Mesdopetam suppresses sensitization and AIMs in the rodent unilateral 6-OHDA lesion model of Parkinson’s disease

P. Svenningsson, Y. Yang, S. Hjorth, S. Waters, N. Waters, P. Svensson, J. Tedroff. Poster presented at the Society for Neuroscience Global Connectome: A virtual event on January 11, 2021.

Preclinical pharmacology of 2-(3-fluoro-5-methanesulfonylphenoxy)ethylamine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson’s disease.

Susanna Waters, Clas Sonesson, Peder Svensson, Joakim Tedroff, Manolo Carta, Elisabeth Ljung, Jenny Gunnergren, Malin Edling, Boel Svanberg, Anne Fagerberg, Johan Kullingsjo, Stephan Hjorth and Nicholas Waters. Journal of Pharmacology and Experimental Therapeutics. May 1, 2020, jpet.119.264226; DOI: https://doi.org/10.1124/jpet.119.264226

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

Per Svenningsson, Anders Johansson, Dag Nyholm, Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson and Joakim Tedroff. npj Parkinson’s Disease 2018;4:35; doi:10.1038/s41531-018-0071-3.

First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.

Rein‐Hedin E, Sjöberg F, Waters S, Sonesson C, Waters N, Huss F, Tedroff J. Clinical Pharmacology in Drug Development. 2021,0 (0);1–10. https://doi.org/10.1002/cpdd.959

(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent

S. Hjorth, S. Waters, N. Waters, J. Tedroff, P. Svensson, A. Fagerberg, M. Edling, B. Svanberg, E. Ljung, J. Gunnergren, S.L. McLean, B. Grayson, N.F. Idris, J.C. Neill and C. Sonesson. The Journal of pharmacology and experimental therapeutics. DOI: https://doi.org/10.1124/jpet.120.000037

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson’s Disease Dementia

Per Svenningsson MD, PhD Per Odin MD, PhD Nil Dizdar MD, PhD Anders Johansson MD, PhD Sotirios Grigoriou MD Panagiota Tsitsi MD Klas Wictorin MD, PhD Filip Bergquist MD, PhD Dag Nyholm MD, PhD Juha Rinne MD, PhD Fredrik Hansson PhD Clas Sonesson PhD Joakim Tedroff MD, PhD for the IRL752 Collaborators. Movement disorder. DOI: https://doi.org/10.1002/mds.28020

A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia [abstract]

P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/a-phase-iia-trial-studying-the-safety-and-tolerability-of-irl752-in-patients-with-parkinsons-disease-dementia/. Accessed September 25, 2019.

Clinical predictions in CNS drug discovery based on in vivo systems response profiles and non-linear machine learning methodology

K. Granbom, F. Wallner, P. Svensson, S. Holm Waters, J. Kullingsjö, N. Waters, A. Andersson. Poster presented at the Society for Neuroscience Global Connectome: A virtual event on January 12, 2021.

In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery

Waters S, Svensson P, Kullingsjö J, Pontén H, Andreasson T, Sunesson Y, Ljung E, Sonesson C, Waters N. ACS Chem Neurosci. 2017 Apr 19;8(4):785-797; doi:10.1021/acschemneuro.6b00371.